Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397 · see citing works

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312 · see citing works

Mapping the Antigenic and Genetic Evolution of Influenza Virus

Smith, D. J., Lapedes, A. S., de Jong, J. C., Bestebroer, T. M., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2004) · Science · doi:10.1126/science.1097211 · Cited by 1,868 · see citing works

Spike mutation D614G alters SARS-CoV-2 fitness

Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., et al. (2021) · Nature · doi:10.1038/s41586-020-2895-3 · Cited by 1,558 · see citing works

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343 · see citing works

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102214 · Cited by 1,257 · see citing works

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., Mizrahi, B., Alroy-Preis, S., Ash, N., Milo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114255 · Cited by 1,169 · see citing works

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01285-x · Cited by 1,147 · see citing works

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

Zang, R., Castro, M. F. G., McCune, B. T., Zeng, Q., Rothlauf, P. W., Sonnek, N. M., Liu, Z., Brulois, K. F., Wang, X., Greenberg, H. B., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc3582 · Cited by 982 · see citing works

Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines

Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.013 · Cited by 927 · see citing works

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

Winkler, E. S., Bailey, A. L., Kafai, N. M., Nair, S., McCune, B. T., Yu, J., Fox, J. M., Chen, R. E., Earnest, J. T., Keeler, S. P., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0778-2 · Cited by 901 · see citing works

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Abu-Raddad, L. J., Chemaitelly, H., & Butt, A. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2104974 · Cited by 899 · see citing works

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881 · see citing works

Animal models for COVID-19

Muñoz-Fontela, C., Dowling, W. E., Funnell, S. G. P., Gsell, P.-S., Riveros-Balta, A. X., Albrecht, R. A., Andersen, H., Baric, R. S., Carroll, M. W., Cavaleri, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2787-6 · Cited by 798 · see citing works

Rapid COVID-19 vaccine development

Graham, B. S. (2020) · Science · doi:10.1126/science.abb8923 · Cited by 771 · see citing works

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

Gu, H., Chen, Q., Yang, G., He, L., Fan, H., Deng, Y.-Q., Wang, Y., Teng, Y., Zhao, Z., Cui, Y., et al. (2020) · Science · doi:10.1126/science.abc4730 · Cited by 762 · see citing works

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Liu, Z., VanBlargan, L. A., Bloyet, L.-M., Rothlauf, P. W., Chen, R. E., Stumpf, S., Zhao, H., Errico, J. M., Theel, E. S., Liebeskind, M. J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.01.014 · Cited by 725 · see citing works

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669 · see citing works

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103055 · Cited by 625 · see citing works

Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., et al. (2021) · doi:10.1101/2021.02.25.21252477 · Cited by 625 · see citing works

SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

Stadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G. A., Tan, J., Bhavsar, D., Capuano, C., Roubidoux, E. K., et al. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.100 · Cited by 623 · see citing works

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science · doi:10.1126/science.abj4176 · Cited by 527 · see citing works

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021

Brown, C., Vostok, J., Johnson, H., Burns, M., Gharpure, R. V., Sami, S., Sabo, R. T., Hall, N. B., Foreman, A., Schubert, P. L., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7031e2 · Cited by 491 · see citing works

SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern

McCallum, M., Bassi, J., De Marco, A., Chen, A., Walls, A. C., Di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., et al. (2021) · Science · doi:10.1126/science.abi7994 · Cited by 412 · see citing works

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

Case, J. B., Rothlauf, P. W., Chen, R. E., Liu, Z., Zhao, H., Kim, A. S., Bloyet, L.-M., Zeng, Q., Tahan, S., Droit, L., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.021 · Cited by 410 · see citing works

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Winkler, E. S., Gilchuk, P., Yu, J., Bailey, A. L., Chen, R. E., Chong, Z., Zost, S. J., Jang, H., Huang, Y., Allen, J. D., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.026 · Cited by 366 · see citing works

Impact of mRNA chemistry and manufacturing process on innate immune activation

Nelson, J., Sorensen, E. W., Mintri, S., Rabideau, A. E., Zheng, W., Besin, G., Khatwani, N., Su, S. V., Miracco, E. J., Issa, W. J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6893 · Cited by 354 · see citing works

SARS-CoV-2 Variants and Vaccines

Krause, P. R., Fleming, T. R., Longini, I. M., Peto, R., Briand, S. C., Heymann, D. L., Beral, V., Snape, M. D., Rees, H., Ropero, A. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmsr2105280 · Cited by 352 · see citing works

Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory

Mateus, J., Dan, J. M., Zhang, Z., Moderbacher, C. R., Lammers, M., Goodwin, B., Sette, A., Crotty, S., & Weiskopf, D. (2021) · doi:10.1101/2021.06.30.21259787 · Cited by 327 · see citing works

Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells

(2021) · doi:10.1126/science.abj9853 · Cited by 327 · see citing works

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2

Amanat, F., Thapa, M., Lei, T., Ahmed, S. M. S., Adelsberg, D. C., Carreño, J. M., Strohmeier, S., Schmitz, A. J., Zafar, S., Zhou, J. Q., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.005 · Cited by 273 · see citing works

Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants

McCallum, M., Walls, A. C., Sprouse, K. R., Bowen, J. E., Rosen, L. E., Dang, H. V., Marco, A. D., Franko, N., Tilles, S. W., Logue, J. K., et al. (2021) · Science · doi:10.1126/science.abl8506 · Cited by 273 · see citing works

Comparison of Two Highly-Effective mRNA Vaccines for COVID-19 During Periods of Alpha and Delta Variant PrevalencePreprint

Puranik, A., Lenehan, P. J., Silvert, E., Niesen, M. J. M., Corchado-García, J., O’Horo, J. C., Virk, A., Swift, M. D., Halamka, J. D., Badley, A. D., et al. (2021) · medRxiv · doi:10.1101/2021.08.06.21261707 · Cited by 243 · see citing works

Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2

Liu, Y., Hu, G., Wang, Y., Ren, W., Zhao, X., Ji, F., Zhu, Y., Feng, F., Gong, M., Ju, X., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025373118 · Cited by 242 · see citing works

Growth, detection, quantification, and inactivation of SARS-CoV-2

Case, J. B., Bailey, A. L., Kim, A. S., Chen, R. E., & Diamond, M. (2020) · Virology · doi:10.1016/j.virol.2020.05.015 · Cited by 230 · see citing works

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

Chen, R. E., Winkler, E. S., Case, J. B., Aziati, I. D., Bricker, T. L., Joshi, A., Darling, T. L., Ying, B., Errico, J. M., Shrihari, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03720-y · Cited by 209 · see citing works

Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy

Yamin, R., Jones, A., Hoffmann, H.-H., Schäfer, A., Kao, K. S., Francis, R., Sheahan, T. P., Baric, R. S., Rice, C. M., Ravetch, J. V., et al. (2021) · Nature · doi:10.1038/s41586-021-04017-w · Cited by 187 · see citing works

Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies

Tada, T., Dcosta, B. M., Samanovic-Golden, M., Herati, R. S., Cornelius, A., Mulligan, M. J., & Landau, N. R. (2021) · doi:10.1101/2021.02.05.430003 · Cited by 153 · see citing works

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes

Tada, T., Dcosta, B. M., Samanovic, M. I., Herati, R. S., Cornelius, A. R., Zhou, H., Vaill, A., Kazmierski, W., Mulligan, M. J., & Landau, N. R. (2021) · mBio · doi:10.1128/mbio.00696-21 · Cited by 152 · see citing works

SARS-CoV-2 immune evasion by variant B.1.427/B.1.429Preprint

McCallum, M., Bassi, J., Marco, A. D., Chen, A., Walls, A. C., di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.31.437925 · Cited by 128 · see citing works

The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human seraPreprint

Rathnasinghe, R., Jangra, S., Čupić, A., Martínez‐Romero, C., Mulder, L. C. F., Kehrer, T., Yildiz, S., Choi, A., Mena, I., Vrieze, J. D., et al. (2021) · medRxiv · doi:10.1101/2021.01.19.21249592 · Cited by 118 · see citing works

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice

Wu, K., Choi, A., Koch, M., Elbashir, S., Ma, L., Lee, D., Woods, A., Henry, C., Palandjian, C., Hill, A., et al. (2021) · doi:10.1101/2021.04.13.439482 · Cited by 101 · see citing works

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice

(2021) · doi:10.1016/j.vaccine.2021.11.001 · Cited by 101 · see citing works

Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge

Muruato, A. E., Vu, M. N., Johnson, B. A., Davis-Gardner, M. E., Vanderheiden, A., Lokugamage, K. G., Schindewolf, C., Crocquet-Valdes, P. A., Langsjoen, R. M., Plante, J. A., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001284 · Cited by 82 · see citing works

Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses

Ibarrondo, F. J., Hofmann, C., Fulcher, J. A., Goodman‐Meza, D., Mu, W., Hausner, M. A., Ali, A., Balamurugan, A., Taus, E., Elliott, J. E., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c03972 · Cited by 78 · see citing works

Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variantsPreprint

McCallum, M., Walls, A. C., Sprouse, K. R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.11.455956 · Cited by 74 · see citing works

Durability of immune responses to the BNT162b2 mRNA vaccine

Suthar, M. S., Arunachalam, P. S., Hu, M., Reis, N., Trisal, M., Raeber, O., Chinthrajah, R. S., Davis-Gardner, M. E., Manning, K. E., Mudvari, P., et al. (2022) · Med · doi:10.1016/j.medj.2021.12.005 · Cited by 60 · see citing works

mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates

Corbett, K. S., Werner, A. P., Connell, S. O., Gagné, M., Lai, L., Moliva, J. I., Flynn, B. J., Choi, A., Koch, M., Foulds, K. E., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01021-0 · Cited by 53 · see citing works

Different Neutralization Sensitivity of SARS-CoV-2 Cell-to-Cell and Cell-Free Modes of Infection to Convalescent Sera

Kruglova, N., Siniavin, A., Gushchin, V., & Mazurov, D. (2021) · Viruses · doi:10.3390/v13061133 · Cited by 37 · see citing works

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · doi:10.1101/2021.01.18.427166

Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics

Longo, S. K., Guo, M. G., Ji, A. L., & Khavari, P. A. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00370-8 · Cited by 1,059 · see citing works

SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

Halfmann, P., Iida, S., Iwatsuki‐Horimoto, K., Maemura, T., Kiso, M., Scheaffer, S. M., Darling, T. L., Joshi, A., Loeber, S. J., Singh, G., et al. (2022) · Nature · doi:10.1038/s41586-022-04441-6 · Cited by 654 · see citing works

SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses

Walls, A. C., Sprouse, K. R., Bowen, J. E., Joshi, A., Franko, N., Navarro, M. J., Stewart, C., Cameroni, E., McCallum, M., Goecker, E. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.011 · Cited by 185 · see citing works

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice

Scheaffer, S. M., Lee, D., Whitener, B., Ying, B., Wu, K., Liang, C.-Y., Jani, H., Martin, P., Amato, N. J., Avena, L. E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02092-8 · Cited by 169 · see citing works

Defining the risk of SARS-CoV-2 variants on immune protection

DeGrace, M. M., Ghedin, E., Frieman, M. B., Krammer, F., Grifoni, A., Alisoltani, A., Alter, G., Amara, R. R., Baric, R. S., Barouch, D. H., et al. (2022) · Nature · doi:10.1038/s41586-022-04690-5 · Cited by 167 · see citing works

Mapping SARS-CoV-2 antigenic relationships and serological responses

Wilks, S. H., Mühlemann, B., Shen, X., Türeli, S., LeGresley, E. B., Netzl, A., Caniza, M. A., Chacaltana-Huarcaya, J. N., Corman, V. M., Daniell, X. G., et al. (2023) · Science · doi:10.1126/science.adj0070 · Cited by 134 · see citing works

Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2

Mackin, S., Desai, P., Whitener, B. M., Karl, C. E., Liu, M., Baric, R. S., Edwards, D. K., Chicz, T. M., McNamara, R. P., Alter, G., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01359-1 · Cited by 114 · see citing works

Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice

Ying, B., Scheaffer, S. M., Whitener, B. M., Liang, C.-Y., Dmytrenko, O., Mackin, S., Wu, K., Lee, D. W., Avena, L. E., Chong, Z., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.037 · Cited by 105 · see citing works

SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies

Reincke, S. M., Yuan, M., Kornau, H., Corman, V. M., van Hoof, S., Sánchez-Sendín, E., Ramberger, M., Yu, W., Hua, Y., Tien, H. J., et al. (2022) · Science · doi:10.1126/science.abm5835 · Cited by 73 · see citing works

COVID-19 Delta Variant: Perceptions, Worries, and Vaccine-Booster Acceptability among Healthcare Workers

Alhasan, K. A., Aljamaan, F., Temsah, M.-H. A., Alshahrani, F. S., Bassrawi, R. K., Alhaboob, A. A. N., Assiri, R., Alenezi, S., Alaraj, A., Alhomoudi, R. I., et al. (2021) · Healthcare · doi:10.3390/healthcare9111566 · Cited by 67 · see citing works

Nasally delivered interferon-λ protects mice against infection by SARS-CoV-2 variants including Omicron

Chong, Z., Karl, C. E., Halfmann, P., Kawaoka, Y., Winkler, E. S., Keeler, S. P., Holtzman, M. J., Yu, J., & Diamond, M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110799 · Cited by 67 · see citing works

Development and applications of mRNA treatment based on lipid nanoparticles

Wang, Z., Ma, W., Fu, X., Qi, Y., Zhao, Y., & Zhang, S. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108130 · Cited by 57 · see citing works

Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B

Liu, J., Budylowski, P., Samson, R., Griffin, B. D., Babuadze, G., Rathod, B., Colwill, K., Abioye, J. A., Schwartz, J. A., Law, R., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj9815 · Cited by 56 · see citing works

Mucosal vaccine-induced cross-reactive CD8+ T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection

Ying, B., Darling, T. L., Desai, P., Liang, C.-Y., Dmitriev, I. P., Soudani, N., Bricker, T. L., Kashentseva, E. A., Harastani, H., Raju, S., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01743-x · Cited by 49 · see citing works

Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma

Henriquez, S., Zerbit, J., Bruel, T., Ouedrani, A., Planas, D., Deschamps, P., Staropoli, I., Hadjadj, J., Varet, B. R., Suarez, F., et al. (2021) · Blood · doi:10.1182/blood.2021013714 · Cited by 44 · see citing works

Engineered mRNA Delivery Systems for Biomedical Applications

Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 44 · see citing works

Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine

Wu, Y., Wang, S., Zhang, Y., Yuan, L., Zheng, Q., Wei, M., Shi, Y., Wang, Z., Ma, J., Wang, K., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.10.011 · Cited by 35 · see citing works

Viral vector and nucleic acid vaccines against COVID-19: A narrative review

Khoshnood, S., Ghanavati, R., Shirani, M., Ghahramanpour, H., Sholeh, M., Shariati, A., Sadeghifard, N., & Heidary, M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.984536 · Cited by 34 · see citing works

Mpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice

Xia, H., He, Y.-R., Zhan, X.-Y., & Zha, G. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105668 · Cited by 33 · see citing works

An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)

Bahrami, A. A., Azargoonjahromi, A., Sadraei, S., Aarabi, A., Payandeh, Z., & Rajabibazl, M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00339-3 · Cited by 32 · see citing works

Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice

Prompetchara, E., Ketloy, C., Alameh, M., Tharakhet, K., Kaewpang, P., Yostrerat, N., Pitakpolrat, P., Buranapraditkun, S., Manopwisedjaroen, S., Thitithanyanont, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37795-0 · Cited by 31 · see citing works

Developing mRNA Nanomedicines with Advanced Targeting Functions

Wang, J., Cai, L., Li, N., Luo, Z., Ren, H., Zhang, B., & Zhao, Y. (2025) · Nano-Micro Letters · doi:10.1007/s40820-025-01665-9 · Cited by 29 · see citing works

Interpretable and Predictive Deep Neural Network Modeling of the SARS-CoV-2 Spike Protein Sequence to Predict COVID-19 Disease Severity

Sokhansanj, B. A., Zhao, Z., & ROSEN, G. L. (2022) · Biology · doi:10.3390/biology11121786 · Cited by 27 · see citing works

A highly efficacious live attenuated mumps virus–based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike

Zhang, Y., Lu, M., Mahesh, K. C., Kim, E., Shamseldin, M. M., Ye, C., Dravid, P., Chamblee, M., Park, J., Hall, J. M., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2201616119 · Cited by 26 · see citing works

An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo

Tsuji, M., Nair, M. S., Masuda, K., Castagna, C., Chong, Z., Darling, T. L., Seehra, K., Hwang, Y., Ribeiro, Á. L., Ferreira, G. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39738-1 · Cited by 25 · see citing works

Impact of administration routes and dose frequency on the toxicology of SARS-CoV-2 mRNA vaccines in mice model

Ahn, J.-H., Lee, J., Roh, G., Lee, N.-Y., Bae, H.-J., Kwon, E., Han, K. M., Kim, J.-E., Park, H., Yoo, S., et al. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03912-1 · Cited by 24 · see citing works

COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects

Zarębska‐Michaluk, D., Hu, C., Brzdęk, M., Flisiak, R., & Rzymski, P. (2022) · Vaccines · doi:10.3390/vaccines10081223 · Cited by 24 · see citing works

Marine natural products and human immunity: novel biomedical resources for anti-infection of SARS-CoV-2 and related cardiovascular disease

Hu, C. (2024) · Natural Products and Bioprospecting · doi:10.1007/s13659-024-00432-4 · Cited by 24 · see citing works

Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern

Akache, B., Renner, T. M., Stuible, M., Rohani, N., Donates, Y. C., Deschatelets, L., Dudani, R., Harrison, B. A., Gervais, C., Hill, J. J., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00540-7 · Cited by 23 · see citing works

Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models

Corleis, B., Hoffmann, D., Rauch, S., Fricke, C., Roth, N., Gergen, J., Kovacikova, K., Schlottau, K., Halwe, N. J., Ulrich, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36110-1 · Cited by 22 · see citing works

A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins

Chonira, V., Kwon, Y. D., Gorman, J., Case, J. B., Ku, Z., Simeon, R. L., Casner, R. G., Harris, D. R., Olia, A. S., Stephens, T., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01193-2 · Cited by 22 · see citing works

Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19

Martin, D. E., Pandey, N., Chavda, P., Singh, G., Sutariya, R., Sancilio, F., & Tripp, R. A. (2023) · Viruses · doi:10.3390/v15071508 · Cited by 22 · see citing works

Mucosal immunization with ChAd-SARS-CoV-2-S prevents sequential transmission of SARS-CoV-2 to unvaccinated hamsters

Darling, T. L., Harastani, H., Joshi, A., Bricker, T. L., Soudani, N., Seehra, K., Hassan, A. O., Diamond, M., & Boon, A. C. M. (2024) · Science Advances · doi:10.1126/sciadv.adp1290 · Cited by 21 · see citing works

Animal models for COVID-19 and tuberculosis

Corleis, B., Bastian, M., Hoffmann, D., Beer, M., & Dorhoi, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1223260 · Cited by 19 · see citing works

Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays

Mühlemann, B., Wilks, S. H., Baracco, L., Bekliz, M., Carreño, J. M., Corman, V. M., Davis-Gardner, M. E., Dejnirattisai, W., Diamond, M., Douek, D. C., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adl1722 · Cited by 18 · see citing works

An HR2-Mimicking Sulfonyl-γ-AApeptide Is a Potent Pan-coronavirus Fusion Inhibitor with Strong Blood–Brain Barrier Permeability, Long Half-Life, and Promising Oral Bioavailability

Xue, S., Xu, W., Wang, L., Wang, X., Duan, Q., Calcul, L., Wang, S., Liu, W., Sun, X., Lu, L., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00313 · Cited by 17 · see citing works

Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron variants in mice and hamsters

Case, J. B., Scheaffer, S. M., Darling, T. L., Bricker, T. L., Adams, L. J., Harastani, H., Trende, R., Sanapala, S., Fremont, D. H., Boon, A. C. M., et al. (2023) · Journal of Virology · doi:10.1128/jvi.00628-23 · Cited by 16 · see citing works

Inside-out assembly of viral antigens for the enhanced vaccination

Cao, F., Peng, S., An, Y., Xu, K., Zheng, T., Dai, L., Ogino, K., Ngai, T., Xia, Y., & Ma, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01414-7 · Cited by 16 · see citing works

Germinal center–mediated broadening of B cell responses to SARS-CoV-2 booster immunization

Malladi, S. K., Jaiswal, D., Ying, B., Alsoussi, W. B., Darling, T. L., Dadonaite, B., Civljak, A., Horvath, S. C., Zhou, J. Q., Kim, W., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adu4107 · Cited by 15 · see citing works

mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2

Darling, T. L., Ying, B., Whitener, B. M., VanBlargan, L. A., Bricker, T. L., Liang, C.-Y., Joshi, A., Bamunuarachchi, G., Seehra, K., Schmitz, A. J., et al. (2022) · Med · doi:10.1016/j.medj.2022.03.009 · Cited by 15 · see citing works

A Live Attenuated COVID-19 Candidate Vaccine for Children: Protection against SARS-CoV-2 Challenge in Hamsters

Mehla, R., Kokate, P., Bhosale, S. R., Vaidya, V., Narayanan, S., Shandil, R. K., Singh, M., Rudramurthy, G. R., Naveenkumar, C. N., Bharathkumar, K., et al. (2023) · Vaccines · doi:10.3390/vaccines11020255 · Cited by 15 · see citing works

Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice

Walls, A. C., VanBlargan, L. A., Wu, K., Choi, A., Navarro, M. J., Lee, D. W., Avena, L. E., Berrueta, D. M., Pham, M. N., Elbashir, S. M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111299 · Cited by 13 · see citing works

GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial

Capone, S., Fusco, F. M., Milleri, S., Borrè, S., Carbonara, S., Caputo, S. L., Leone, S., Gori, G., Maggi, P., Cascio, A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101084 · Cited by 13 · see citing works

A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamstersPreprint

Ying, B., Darling, T. L., Desai, P., Liang, C.-Y., Dmitriev, I. P., Soudani, N., Bricker, T. L., Kashentseva, E. A., Harastani, H., Schmidt, A. G., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.04.539332 · Cited by 13 · see citing works

Intestinal helminth infection impairs vaccine-induced T cell responses and protection against SARS-CoV-2 in mice

Desai, P., Karl, C. E., Ying, B., Liang, C.-Y., García‐Salum, T., Santana, A. C., ten-Caten, F., Urban, J. F., Elbashir, S. M., Edwards, D. K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ado1941 · Cited by 12 · see citing works

The immunobiology of SARS-CoV-2 infection and vaccine responses: potential influences of cross-reactive memory responses and aging on efficacy and off-target effects

Collins, C. P., Longo, D. L., & Murphy, W. J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1345499 · Cited by 9 · see citing works

Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins

Chen, J., Wang, X., Li, L., Yi, L., Jiang, Y., Hao, P., Xu, Z., Zou, W., Li, P., Gao, Z., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.967493 · Cited by 9 · see citing works

Evaluating infectious disease outbreak potential and mitigation effectiveness on cruise ships

Mosleh, R., Haskuee, M. B., Ghasemi, A., Grunnill, M. D., Arino, J., Tofighi, M., Thommes, E. W., & Wu, J. (2024) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2024.111875 · Cited by 8 · see citing works

Enantiomer-dependent and modification-free DNA matrix as an adjuvant for subunit vaccines against SARS-CoV-2 or pneumococcal infections

Li, C., Li, Y., Zhou, B., Li, T., Wei, X., Chen, K., Chen, W., Shi, Z., Dai, X., Zhang, J., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01431-7 · Cited by 7 · see citing works

Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results

Бекболатович, К. Л., Myrzakhmetova, B. S., Tussipova, A. A., Жаппарова, Г. А., Tlenchiyeva, T. M., Bissenbayeva, K. B., Zhapar, K., Zhugunissov, K. D., Nurabayev, S. S., & Kerimbayev, A. A. (2024) · Vaccines · doi:10.3390/vaccines12121401 · Cited by 7 · see citing works

Approaches to evaluate the specific immune responses to SARS-CoV-2

López-Gomez, A., Pelaez-Prestel, H. F., & Juárez, I. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.09.033 · Cited by 7 · see citing works

Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responsesPreprint

Walls, A. C., Sprouse, K. R., Joshi, A., Bowen, J. E., Franko, N., Navarro, M. J., Stewart, C., McCallum, M., Goecker, E. A., Degli-Angeli, E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.08.471707 · Cited by 7 · see citing works

mRNA prime-boost vaccination promotes clonal continuity in germinal center reactions and broadens SARS-CoV-2 variant coverage

Ciancaglini, M., Fixemer, J., Seven, C., Dimitrova, M., Finozzi, D., Weklak, D., Kastner, A. L., Jönsson, F., Wagner, I., Vincenti, I., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.008 · Cited by 6 · see citing works

Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval

Miyamoto, S., Kuroda, Y., Kanno, T., Ueno, A., Shiwa-Sudo, N., Iwata‐Yoshikawa, N., Sakai, Y., Nagata, N., Arashiro, T., Ainai, A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106694 · Cited by 6 · see citing works

A binary self-amplifying expression platform enabling lipid nanoparticle-free vaccines and nanomedicines

Jefferies, W. A., Choi, K. B., Ribeca, P., Kari, S., Young, J. B., Hui, E., Qi, S. Y., Garrovillas, E., Fan, J., Cho, B. M. Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66252-3 · Cited by 5 · see citing works

Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters

Bricker, T. L., Joshi, A., Soudani, N., Scheaffer, S. M., Patel, N., Guebre‐Xabier, M., Smith, G., Diamond, M., & Boon, A. C. M. (2024) · Journal of Virology · doi:10.1128/jvi.01206-23 · Cited by 5 · see citing works

DNA-based vaccines: Advances, applications, and future prospects

Zhou, Z. P., Chen, Z. R., Bandara, R. A., Duan, R. C., Cao, H., Liu, J., & Hu, J. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2025.102025 · Cited by 4 · see citing works

Cholesterol in mRNA‐Lipid Nanoparticles can be Replaced with the Synthetic Mycobacterial Monomycoloyl Glycerol Analogue MMG‐1

Lokras, A. G., Baghel, S. S., Jensen, R. F., Thakur, A., Franzyk, H., Thofte, O., Herrera‐Barrera, M., Landry, M. R., Ongun, M., Tami, A., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202505627 · Cited by 4 · see citing works

Broad neutralizing antibody response of a monomeric spike–based SARS-CoV-2 bivalent vaccine against diverse variants

Wang, S., Sun, H., Wang, Y., Wang, Z., Yuan, L., Guo, H., Gao, J., Lan, M., Wu, Y., Shang, H., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2503254122 · Cited by 4 · see citing works

A Unique mRNA Vaccine Elicits Protective Efficacy against the SARS-CoV-2 Omicron Variant and SARS-CoV

Guan, X., Verma, A. K., Wang, G., Roy, A., Perlman, S. M., & Du, L. (2024) · Vaccines · doi:10.3390/vaccines12060605 · Cited by 4 · see citing works

A trimeric spike-based COVID-19 vaccine candidate induces broad neutralization against SARS-CoV-2 variants

Gao, F., Zheng, M., Fan, J., Ding, Y., Liu, X., Zhang, M., Zhang, X., Dong, J., Zhou, X., Luo, J. F., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2186110 · Cited by 4 · see citing works

Poor immunogenicity upon SARS-CoV-2 mRNA vaccinations in autoimmune SLE patients is associated with pronounced EF-mediated responses and anti-BAFF/Belimumab treatmentPreprint

Faliti, C. E., Anam, F. A., Cheedarla, N., Woodruff, M. C., Usman, S. Y., Runnstrom, M. C., Van, T. T. P., Kyu, S. Y., Ahmed, H., Morrison-Porter, A., et al. (2023) · medRxiv · doi:10.1101/2023.06.08.23291159 · Cited by 4 · see citing works

Epitope-focused discovery of SARS-CoV-2 antibodies that potently neutralize Omicron variants

Zost, S. J., Suryadevara, N., Williamson, L. E., Scheaffer, S. M., Binshtein, E., Buchman, C. D., Johnson, N. V., Catanzaro, N., Ravera, S., Chapman, N. S., et al. (2026) · Nature Microbiology · doi:10.1038/s41564-026-02282-x · Cited by 3 · see citing works

The Alterations of Serum N-glycome in Response to SARS-CoV-2 Vaccination

Dojcsák, D., Kardos, Z., Szabó, M., Oláh, C., Körömi, Z., Viskolcz, B., & Váradi, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076203 · Cited by 3 · see citing works

Research progress in mRNA drug modification and delivery systems

Zhou, Z., & Li, X. (2023) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2023-0101 · Cited by 3 · see citing works

Discovery of Coronavirus Main Protease Inhibitors with Enhanced Brain Exposure and Potent Oral Efficacy in SARS-CoV-2 and MERS Infection Models

Lizzadro, L., Li, J., Taha, T. Y., Degotte, G., Detomasi, T. C., Belinchón, F. J. Z., Hantz, E. R., Huang, S., Matsui, Y., Henderson, W. R., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03015 · Cited by 2 · see citing works

A new mRNA antigen vaccine induces potent B and T cell responses and in vivo protection against SARS-CoV-2

Wen, J., Moon, J., Tucciarone, L., Bu, T.-H., Sun, A. Y., Miller, R., Timis, J., Wu, L., Smith, D. M., Shresta, S., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01421-z · Cited by 2 · see citing works

Upper Respiratory Infection Drives Clinical Signs and Inflammatory Responses Following Heterologous Challenge of SARS-CoV-2 Variants of Concern in K18 Mice

Nichols, J. H., Williams, E. P., Parvathareddy, J., Cao, X., Kong, Y., Fitzpatrick, E. A., Webby, R. J., & Jonsson, C. B. (2023) · Viruses · doi:10.3390/v15040946 · Cited by 1 · see citing works

Structural and functional properties of the SARS-CoV-2 spike protein: Potential vaccine and drug development for COVID-19

Berkowitz, R. L., & Ostrov, D. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19170-1.00013-9 · Cited by 1 · see citing works

SARS-CoV-2 Omicron (B.1.1.529) Variant: No Time to Wait!

Rahmani, S., & Rezaei, N. (2022) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v93i2.12712 · Cited by 1 · see citing works

An Immunostimulatory Glycolipid That Blocks SARS-CoV-2, RSV, and Influenza Infections In VivoPreprint

Ho, D. D., Tsuji, M., Nair, M. S., Masuda, K., Castagna, C., Chong, Z., Darling, T. L., Seehra, K., Ribeiro, Á. L., Ferreira, G. M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1785892/v1

An Immunostimulatory Glycolipid That Blocks SARS-CoV-2, RSV, and Influenza Infections In VivoPreprint

Ho, D. D., Tsuji, M., Nair, M. S., Masuda, K., Castagna, C., Chong, Z., Darling, T. L., Seehra, K., Ribeiro, Á. L., Ferreira, G. M., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-1785892/v2

A novel SARS-CoV-2 Beta RBD DNA vaccine directly targeted to antigen-presenting cells induces strong humoral and T cell responses

Kuczkowska, K., Bjerkan, L., Stubsrud, E., Husbyn, H., Chellappa, S., Hauge, A., Skarshaug, R., Torgersen, M. L., Heim, J. B., Jørgensen, M. J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46223-8

SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect against evolving variants.

Carroll, M. L., Fox, H. R., Tran, A., Chellappan, G., Rojas, L. V., Karengil, G., Karandish, F., Langston, J. W., Fall, B. M., Whalen, M. M., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126988

A broad-spectrum SARS-CoV-2 RBD vaccine with selected high-impact mutations and novel adjuvant induces durable T cell response and broad protection in mice

Chen, X., Zhang, Y., Yang, S., Chen, Y., Qian, S., Zhang, Z., Liu, Q., 马成宝, 余为一, Feng, J., et al. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1690554

“Drug-Delivering-Drug” nanocomplexes reinforce cytosolic nucleic acid sensing for broad-spectrum antiviral activity in fish

Ma, B., Yao, W., Fu, X., Niu, Y., Chang, O., Yang, K., Liang, H., Luo, X. H., Xiao, W., Lin, Q., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04750-2

In vitro transcription for RNA vaccines and therapeutics: a quality-by-design perspective on manufacturability

Nair, A., & Kis, Z. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.109034

Nasally delivered interferon lambda protects mice against SARS-CoV-2 infection

Kawaoka, Y. (2024) · ImmPort · doi:10.21430/m3fgea29gm

Immunization with JN.1 spike protein increases the breadth of binding and neutralizing antibodies in Syrian hamsters in an immune-history dependent manner

Darling, T. L., Liang, C.-Y., Hastings, I., Soudani, N., Bricker, T. L., Suthar, M. S., Ellebedy, A. H., Diamond, M. S., & Boon, A. C. M. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.129310

mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2

Darling, T. L., Ying, B., Whitener, B. M., VanBlargan, L. A., Bricker, T. L., Liang, C.-Y., Joshi, A., Bamunuarachchi, G., Seehra, K., Schmitz, A. J., et al. (2022) · Med · doi:10.1016/j.medj.2022.03.009 · Cited by 15 · see citing works

Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice

Ying, B., Scheaffer, S. M., Whitener, B. M., Liang, C.-Y., Dmytrenko, O., Mackin, S., Wu, K., Lee, D. W., Avena, L. E., Chong, Z., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.037 · Cited by 105 · see citing works

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science · doi:10.1126/science.abj4176 · Cited by 527 · see citing works

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice

(2021) · doi:10.1016/j.vaccine.2021.11.001 · Cited by 101 · see citing works

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice

Scheaffer, S. M., Lee, D., Whitener, B., Ying, B., Wu, K., Liang, C.-Y., Jani, H., Martin, P., Amato, N. J., Avena, L. E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02092-8 · Cited by 169 · see citing works